Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.71 USD
Change Today +0.0288 / 4.23%
Volume 42.7K
As of 8:10 PM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

sanofi cvr (GCVRZ) Snapshot

Open
$0.68
Previous Close
$0.68
Day High
$0.71
Day Low
$0.67
52 Week High
11/17/14 - $1.06
52 Week Low
07/31/14 - $0.40
Market Cap
--
Average Volume 10 Days
183.6K
EPS TTM
--
Shares Outstanding
236.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SANOFI CVR (GCVRZ)

sanofi cvr (GCVRZ) Details

Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, including Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, as well as Toujeo, an insulin glargine. The company also offers Cerezyme to treat gaucher disease; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis type I, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers; Thymoglobulin to treat acute rejection in organ transplantation, aplastic anemia, and graft-versus-host diseases; Eloxatin for colorectal cancer; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix for atherothrombosis and acute coronary syndrome; Lovenox for the treatment and prevention of deep vein thrombosis and acute coronary syndromes; Aprovel/CoAprovel for hypertension; Renagel/Renvela to treat chronic kidney disease; Depakine for epilepsy; Synvisc/Synvisc-One for the treatment of pain associated with osteoarthritis of the knee; Stilnox/Ambien/Myslee to treat sleep disorders; Multaq for atrial fibrillation; Allegra for the treatment of allergic rhinitis and urticarial; Actonel for osteoporosis and paget's disease; and Auvi-Q/Allerject for the treatment of severe allergic reactions. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

113,496 Employees
Last Reported Date: 03/11/15
Founded in 1973

sanofi cvr (GCVRZ) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sanofi cvr (GCVRZ) Key Developments

Zhejiang Hisun Pharmaceutical and Sanofi Enter Agreement on Diabetes Drug Development

Zhejiang Hisun Pharmaceutical has signed an agreement with Sanofi to explore potential coooperation in diabetes treatment. Under the agreement, the two companies may set up a joint venture in mainland China for manufacturing insulin, insulin analogues as well as develop and commercialise other diabetes therapies.

PENDOPHARM Enters into Distribution Agreement with Sanofi Canada

PENDOPHARM announced an agreement with Sanofi Canada concerning exclusive rights to market and distribute non-prescription Nasacort® Allergy 24HR on the Canadian market.

Sanofi Presents at BIO International Convention 2015, Jun-17-2015 10:45 AM

Sanofi Presents at BIO International Convention 2015, Jun-17-2015 10:45 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Tanja WEBER, VP Corporate Oncology Business Development.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GCVRZ:US $0.71 USD +0.0288

GCVRZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $68.22 USD +0.01
Amgen Inc $154.50 USD +1.24
Bayer AG €123.20 EUR +0.128
Bristol-Myers Squibb Co $67.50 USD +0.02
Novo Nordisk A/S kr368.40 DKK -2.60
View Industry Companies
 

Industry Analysis

GCVRZ

Industry Average

Valuation GCVRZ Industry Range
Price/Earnings 28.0x
Price/Sales 3.4x
Price/Book 2.1x
Price/Cash Flow 17.7x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI CVR, please visit www.sanofi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.